

Grzegorz S Nowakowski

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5724707/grzegorz-s-nowakowski-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

235
papers

3,077
citations

29
h-index

53
g-index

250
ext. papers

4,024
ext. citations

3.5
avg, IF

5
L-index

#	Paper	IF	Citations
235	Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials.. <i>Blood Cancer Journal</i> , 2022 , 12, 1	7	
234	What Prognostic Markers Should Be Evaluated in Marginal Zone Lymphoma? A Survey Among Leading International Experts.. <i>HemaSphere</i> , 2022 , 6, e680	0.3	
233	67-Year-Old Woman With Diarrhea and Weight Loss.. <i>Mayo Clinic Proceedings</i> , 2022 , 97, 364-369	6.4	
232	Immune Epigenetic Crosstalk Between Malignant B Cells and the Tumor Microenvironment in B Cell Lymphoma.. <i>Frontiers in Genetics</i> , 2022 , 13, 826594	4.5	1
231	Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment.. <i>Current Treatment Options in Oncology</i> , 2022 , 23, 155-170	5.4	1
230	Finding a consensus on time-to-event endpoints definitions in Marginal Zone Lymphoma: a Delphi method.. <i>Hematological Oncology</i> , 2022 ,	1.3	
229	PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts.. <i>Blood Cancer Journal</i> , 2022 , 12, 78	7	0
228	Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care.. <i>JCO Oncology Practice</i> , 2022 , OP2100789	2.3	
227	RNAseq identification of FISH-cryptic BCL6::TP63 rearrangement in ALK-negative anaplastic large cell lymphoma.. <i>Histopathology</i> , 2022 ,	7.3	0
226	Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2200754	2.2	2
225	Parsaclisib in Combination with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Preliminary Results of a Phase 1/1b Study. <i>Blood</i> , 2021 , 138, 1415-1415	2.2	1
224	A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL). <i>Blood</i> , 2021 , 138, 1420-1420	2.2	0
223	Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021 , 138, 183-183	2.2	2
222	Safety and efficacy of durvalumab with R-CHOP or R-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial. <i>International Journal of Hematology</i> , 2021 , 1	2.3	0
221	Central Nervous System Involvement By Mantle Cell Lymphoma. <i>Blood</i> , 2021 , 138, 2426-2426	2.2	0
220	Brentuximab Vedotin in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ECHELON-3, Trial in Progress). <i>Blood</i> , 2021 , 138, 3564-3564	2.2	
219	Mismatch-Repair Deficiency in Follicular Lymphoma Tumors Is Common and Associated with a Favorable Overall Survival. <i>Blood</i> , 2021 , 138, 3523-3523	2.2	

218	Impact of Novel Agents on the Outcomes of Patients with Classic Hodgkin Lymphoma That Relapsed after Autologous Stem Cell Transplant. <i>Blood</i> , 2021 , 138, 1373-1373	2.2	
217	Event-Free Survival at 24 Months (EFS24) Becomes an Important Clinical Endpoint in Newly Diagnosed Mantle Cell Lymphoma in the New Era. <i>Blood</i> , 2021 , 138, 2429-2429	2.2	1
216	Characteristics, Management and Outcomes of Patients with Intravascular Lymphoma: A Mayo Clinic Experience. <i>Blood</i> , 2021 , 138, 1452-1452	2.2	
215	The Impact of Prior Treatment with a CD19 Targeting Monoclonal Antibody on Subsequent Treatment with CD19 Targeting CART Cell Therapy in Preclinical Models. <i>Blood</i> , 2021 , 138, 2412-2412	2.2	0
214	Time to Refractory Status Defines Subsets of Primary Refractory Diffuse Large B-Cell Lymphoma with Distinct Outcomes. <i>Blood</i> , 2021 , 138, 2524-2524	2.2	
213	Impact of Diagnosis-to-Treatment Interval on Overall Survival in Patients with Mantle Cell Lymphoma: A National Cancer Database Analysis. <i>Blood</i> , 2021 , 138, 3549-3549	2.2	
212	PET2 Response Associated with Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Results of Two Independent Prospective Cohorts. <i>Blood</i> , 2021 , 138, 2508-2508	2.2	
211	A Prospective Multicenter Study of Minimal Residual Disease Assessment Using a Next-Generation Immunosequencing Assay and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021 , 138, 52-52	2.2	0
210	First-Mind: Primary Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021 , 138, 3556-3556	2.2	0
209	Barriers to Enrollment in Clinical Trials in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma That Progressed after Anti-CD19 CART Cell Therapy. <i>Blood</i> , 2021 , 138, 2527-2527	2.2	1
208	Aspirin and other nonsteroidal anti-inflammatory drugs, statins and risk of non-Hodgkin lymphoma. <i>International Journal of Cancer</i> , 2021 , 149, 535-545	7.5	0
207	Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis in the rituximab era. <i>Blood Advances</i> , 2021 , 5, 1379-1387	7.8	7
206	Relapsed/Refractory International Prognostic Index (R/R-IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2021 , 96, 599-605	7.1	1
205	Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1329-1338	2.2	19
204	ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1317-1328	2.2	32
203	Diffuse large B-cell lymphoma: new targets and novel therapies. <i>Blood Cancer Journal</i> , 2021 , 11, 68	7	13
202	Brentuximab vedotin in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (Trials in Progress).. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS7571-TPS7571	2.2	0
201	Impact of time to relapse and response to salvage therapy on post autologous stem cell transplant outcomes in relapsed or refractory diffuse large B-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e19501-e19501	2.2	

200	Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e19547-e19547	2.2	0
199	Survival trends of older adult patients with diffuse large B-cell lymphoma: A National Cancer Database analysis.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 7542-7542	2.2	
198	Type of tissue biopsy and outcomes in diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2021 , 39, e13569-e13569	2.2	0
197	Salvage therapies in transplant-eligible relapsed classic Hodgkin lymphoma, are novel regimens better?. <i>Journal of Clinical Oncology</i> , 2021 , 39, 7530-7530	2.2	
196	Progression-free survival at 24 months as a landmark after autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 7522-7522	2.2	1
195	Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1641-1649	2.2	5
194	Outcomes in mantle cell lymphoma with central nervous system involvement.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e19527-e19527	2.2	0
193	First-MIND: A phase Ib, open-label, randomized study to assess safety of tafasitamab (tafa) or tafa + lenalidomide (LEN) in addition to R-CHOP in patients with newly diagnosed DLBCL.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 7540-7540	2.2	2
192	Diffuse large B-cell lymphoma with leukemic involvement.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e19552-e19552		
191	Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era. <i>American Journal of Hematology</i> , 2021 , 96, 979-988	7.1	1
190	Safety and efficacy of VIP152, a CDK9 inhibitor, in patients with double-hit lymphoma (DHL).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 7538-7538	2.2	1
189	Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2021 , 96, 945-953	7.1	2
188	Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era. <i>Blood Cancer Journal</i> , 2021 , 11, 133	7	1
187	Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma. <i>Blood Cancer Journal</i> , 2021 , 11, 130	7	5
186	Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. <i>Leukemia</i> , 2021 , 35, 522-533	10.7	9
185	American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care. <i>Journal of Clinical Oncology</i> , 2021 , 39, 155-169	2.2	38
184	Testicular FDG-PET/CT uptake threshold in aggressive lymphomas. <i>American Journal of Hematology</i> , 2021 , 96, E81-E83	7.1	0
183	Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma. <i>Blood Cancer Journal</i> , 2021 , 11, 8	7	1

182	A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies. <i>Leukemia and Lymphoma</i> , 2021 , 62, 2625-2636	1.9	0
181	RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2021 , 27, 6124-6134	12.9	7
180	Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type. <i>Hematological Oncology</i> , 2021 , 39, 658-663	1.3	1
179	Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2021 , 195, 210-216	4.5	5
178	Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study. <i>Blood Cancer Journal</i> , 2021 , 11, 160	7	0
177	Recently approved drugs herald a new era in therapy for diffuse large B-cell lymphoma. <i>Clinical Advances in Hematology and Oncology</i> , 2021 , 19, 284-287	0.6	0
176	Treatment of Aggressive B Cell Lymphomas: Updates in 2019. <i>Current Hematologic Malignancy Reports</i> , 2020 , 15, 225-234	4.4	5
175	A practical approach to FISH testing for MYC rearrangements and brief review of MYC in aggressive B-cell lymphomas. <i>Journal of Hematopathology</i> , 2020 , 13, 127-135	0.4	1
174	ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1. <i>Future Oncology</i> , 2020 , 16, 991-999	3.6	6
173	Central Nervous System (CNS) Involvement of Richter Transformation: A Single Center Experience. <i>Blood</i> , 2020 , 136, 3-4	2.2	
172	Estimation of Long-Term Survival with Tafasitamab + Lenalidomide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020 , 136, 9-10	2.2	
171	A Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of a Novel IRAK4 Inhibitor CA-4948 in Combination with Ibrutinib, in Patients with Relapsed or Refractory Hematologic Malignancies. <i>Blood</i> , 2020 , 136, 49-50	2.2	0
170	Lenalidomide/RCHOP (R2CHOP) Produces High Response Rates and Overall Survival in New, Untreated Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma- Results from MC078E. <i>Blood</i> , 2020 , 136, 47-48	2.2	
169	Clonal Somatic Mutations Are a Biomarker for Inferior Prognosis in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020 , 136, 26-27	2.2	0
168	Waldenström Macroglobulinemia in the Very Elderly (≥75 years):Clinical Characteristics and Outcomes. <i>Blood</i> , 2020 , 136, 44-45	2.2	
167	A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Analysis of the Safety Run-in Phase. <i>Blood</i> , 2020 , 136, 27-33	2.2	1
166	Safety, Pharmacokinetics and Activity of CA-4948, an IRAK4 Inhibitor, for Treatment of Patients with Relapsed or Refractory Hematologic Malignancies: Results from the Phase 1 Study. <i>Blood</i> , 2020 , 136, 44-45	2.2	3
165	Estimates and Timing of Therapy Initiation during the First Decade for Patients with Follicular Lymphoma Who Were Observed at Diagnosis. <i>Blood</i> , 2020 , 136, 7-8	2.2	2

164	RE-MIND study: A propensity score-based 1:1 matched comparison of tafasitamab + lenalidomide (L-MIND) versus lenalidomide monotherapy (real-world data) in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 8020-8020	2.2	7
163	Mayo Clinic Hematology Fellowship for Advanced Practice Providers. <i>Journal of the Advanced Practitioner in Oncology</i> , 2020 , 11, 395-400	0.7	0
162	Human Pegivirus Infection and Lymphoma Risk: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2020 , 71, 1221-1228	11.6	12
161	Targetability of STAT3-JAK2 fusions: implications for T-cell lymphoproliferative disorders of the gastrointestinal tract. <i>Leukemia</i> , 2020 , 34, 1467-1471	10.7	2
160	Impact of MYD88 mutation status on histological transformation of Waldenström Macroglobulinemia. <i>American Journal of Hematology</i> , 2020 , 95, 274-281	7.1	18
159	Predictors of short-term survival in Waldenström Macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2975-2979	1.9	1
158	Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients. <i>Blood Cancer Journal</i> , 2020 , 10, 117	7	4
157	Analysis and impact of a multidisciplinary lymphoma virtual tumor board. <i>Leukemia and Lymphoma</i> , 2020 , 61, 3351-3359	1.9	3
156	Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials: A Systematic Review and Meta-analysis. <i>JAMA Network Open</i> , 2020 , 3, e2012534	10.4	26
155	Variable global distribution of cell-of-origin from the ROBUST phase III study in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2020 , 105, e72-e75	6.6	5
154	Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease. <i>Haematologica</i> , 2020 , 105, 348-357	6.6	46
153	Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?. <i>Leukemia and Lymphoma</i> , 2020 , 61, 318-327	1.9	5
152	A Graduate-Level Interdisciplinary Curriculum in CAR-T Cell Therapy. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2020 , 4, 203-210	3.1	3
151	Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2019 , 9, 73	7	19
150	Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1819-1827	2.2	25
149	Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma. <i>British Journal of Haematology</i> , 2019 , 186, 820-828	4.5	9
148	Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2019 , 9, 48	7	13
147	Detection of extranodal and spleen involvement by FDG-PET imaging predicts adverse survival in untreated follicular lymphoma. <i>American Journal of Hematology</i> , 2019 , 94, 786-793	7.1	10

146	Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis. <i>JAMA Oncology</i> , 2019 , 5, 1008-1019	13.4	288
145	AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1188-1199	2.2	165
144	A case of ibrutinib-associated aspergillosis presenting with central nervous system, myocardial, pulmonary, intramuscular, and subcutaneous abscesses. <i>Leukemia and Lymphoma</i> , 2019 , 60, 559-561	1.9	8
143	T cell/histiocyte-rich large B cell lymphoma: incidence, demographic disparities, and long-term outcomes. <i>British Journal of Haematology</i> , 2019 , 185, 140-142	4.5	7
142	Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma. <i>Blood</i> , 2019 , 134, 1289-1297	2.2	19
141	End-of-Treatment PET/Computed Tomography Response in Diffuse Large B-Cell Lymphoma. <i>PET Clinics</i> , 2019 , 14, 307-315	2.2	2
140	Subgroup Analyses of Elderly Patients Aged ≥70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL). <i>Blood</i> , 2019 , 134, 347-347	2.2	2
139	Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies. <i>Blood</i> , 2019 , 134, 4092-4092	2.2	1
138	Age and Time to Progression Predict Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Progress Following Frontline Immunochemotherapy (IC). <i>Blood</i> , 2019 , 134, 400-400	2.2	2
137	Engine: Phase III Randomized Study of Enzastaurin/R-CHOP Versus Placebo/R-CHOP in Frontline High Risk Diffuse Large B Cell Lymphoma Patients with Novel Genomic Biomarker DGM1. <i>Blood</i> , 2019 , 134, 5330-5330	2.2	1
136	A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma. <i>Blood</i> , 2019 , 134, 467-467	2.2	16
135	Intrafollicular CD4+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma. <i>Blood</i> , 2019 , 134, 121-121	2.2	7
134	A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: The First-Mind Trial. <i>Blood</i> , 2019 , 134, 2877-2877	2.2	3
133	Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma: A Phase 2 Study. <i>Blood</i> , 2019 , 134, 4090-4090	2.2	1
132	Comparative Assessment of Surface CD19 and CD20 Expression on B-Cell Lymphomas from Clinical Biopsies: Implications for Targeted Therapies. <i>Blood</i> , 2019 , 134, 5345-5345	2.2	10
131	Targeting of CD19 By Tafasitamab Does Not Impair CD19 Directed Chimeric Antigen Receptor T Cell Activity in Vitro. <i>Blood</i> , 2019 , 134, 2859-2859	2.2	4
130	Clinical Features and Treatment for Neurolymphomatosis in the Rituximab Era: Single Institution Experience. <i>Blood</i> , 2019 , 134, 4129-4129	2.2	1
129	Phase 1 Dose-Finding Study Investigating CA-4948, an IRAK4 Kinase Inhibitor, in Patients with R/R NHL: Report of Initial Efficacy and Updated Safety Information. <i>Blood</i> , 2019 , 134, 5327-5327	2.2	3

128	Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?. <i>Blood</i> , 2019 , 134, 1532-1532		
127	Quality of Life Was Not Negatively Impacted By the Addition of Lenalidomide to R-CHOP Chemotherapy (R2-CHOP) Compared with Placebo Plus R-CHOP Chemotherapy in Patients with Previously Untreated Activated B-Cell (ABC)-Type Diffuse Large B-Cell Lymphoma (DLBCL): Health-Related Quality of Life (HRQL) Analysis of the International Robust Study. <i>Blood</i> , 2019 , 134, 5352-5352	2.2	
126	Characteristics of Patients with Relapsed/Refractory Burkitt Non-Hodgkin Lymphoma (NHL): Impact on the Feasibility of CAR-T Cell Therapy. <i>Blood</i> , 2019 , 134, 5352-5352	2.2	
125	Genetic Risk Factors for Cardiovascular Disease in Adult Lymphoma Patients. <i>Blood</i> , 2019 , 134, 5215-5215	2.2	
124	Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2019 , 134, 919-919	2.2	
123	Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse. <i>Blood</i> , 2019 , 134, 923-923	2.2	
122	Genomic Analysis of R2CHOP-Treated DLBCL Reveals a High-Risk Population Driven By Inflammatory Pathways. <i>Blood</i> , 2019 , 134, 1480-1480	2.2	
121	Prevalence and the Impact of Hypogammaglobulinemia in Newly Diagnosed, Untreated Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2019 , 134, 1604-1604	2.2	1
120	Treatment and Lifestyle Risk Factors for Cardiovascular Disease Post Lymphoma Diagnosis: A Prospective Study in the Modern Treatment Era. <i>Blood</i> , 2019 , 134, 422-422	2.2	
119	Central Nervous System Involvement in Peripheral T-Cell Lymphoma. <i>Blood</i> , 2019 , 134, 5293-5293	2.2	
118	Pretreatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing Chemotherapy. <i>Clinical Epidemiology</i> , 2019 , 11, 987-996	5.9	3
117	Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. <i>Leukemia</i> , 2019 , 33, 790-794	10.7	16
116	Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018. <i>American Journal of Hematology</i> , 2019 , 94, 291-298	7.1	24
115	Identification of Factors Associated with Hematology-Oncology Fellow Academic Success and Career Choice. <i>Journal of Cancer Education</i> , 2019 , 34, 1219-1224	1.8	5
114	Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. <i>European Journal of Cancer</i> , 2018 , 93, 57-68	7.5	37
113	Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era. <i>Blood Cancer Journal</i> , 2018 , 8, 27	7	9
112	Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era. <i>British Journal of Haematology</i> , 2018 , 183, 149-152	4.5	3
111	History of autoimmune conditions and lymphoma prognosis. <i>Blood Cancer Journal</i> , 2018 , 8, 73	7	19

110	The diagnosis and treatment of primary vitreoretinal lymphoma: a review. <i>International Journal of Retina and Vitreous</i> , 2018 , 4, 18	2.9	54
109	Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma. <i>Journal of Hematology and Oncology</i> , 2018 , 11, 57	22.4	12
108	Inferior survival in high-grade B-cell lymphoma with and and/or rearrangements is not associated with gene rearrangements. <i>Haematologica</i> , 2018 , 103, 1899-1907	6.6	31
107	A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, 664-672.e2	2	4
106	AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. <i>Blood</i> , 2018 , 132, 445-445	2.2	8
105	An Analysis of a Multidisciplinary Lymphoma Virtual Tumor Board with Regional and International Participation. <i>Blood</i> , 2018 , 132, 2247-2247	2.2	2
104	Relapses after Achieving EFS24 in Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era. <i>Blood</i> , 2018 , 132, 454-454	2.2	1
103	Short Time between Progression after Immunochemotherapy and Initiation of Salvage Therapy (PTI) Is Associated with Inferior Long-Term Outcomes in Patients with Relapsed/Refractory DLBCL. <i>Blood</i> , 2018 , 132, 4204-4204	2.2	1
102	Preclinical Activity of IRAK4 Kinase Inhibitor CA-4948 Alone or in Combination with Targeted Therapies and Preliminary Phase 1 Clinical Results in Non-Hodgkin Lymphoma. <i>Blood</i> , 2018 , 132, 4168-4168	2.2	4
101	High Efficacy of Lenalidomide Plus R-CHOP (R2CHOP) Combination in First Line Treatment of Activated B-Cell (ABC) DLBCL Defined Using Gene-Expression Profiling: A Combined Analysis from Two Phase 2 Trials. <i>Blood</i> , 2018 , 132, 2962-2962	2.2	1
100	Lenalidomide in Combination with Standard R-CHOP Overcomes the Negative Prognostic Value of Peripheral Blood Absolute Lymphocyte/Monocyte Ratio at Diagnosis and during Treatment in Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2018 , 132, 4139-4139	2.2	
99	Clinical Significance of Testicular FDG-PET/CT Uptake in Aggressive Lymphomas. <i>Blood</i> , 2018 , 132, 5401-5401	2.2	1
98	Non-Diffuse Large B-Cell Primary Central Nervous System Lymphoma. <i>Blood</i> , 2018 , 132, 4208-4208	2.2	
97	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018 , 132, 2884-2884	2.2	1
96	Epstein-Barr Virus Status in Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder. <i>Blood</i> , 2018 , 132, 2979-2979	2.2	
95	Development of a Hematology-Specific Fellowship Curriculum for Advanced Practice Providers Utilizing a Needs-Based Assessment. <i>Blood</i> , 2018 , 132, 2236-2236	2.2	
94	Patterns of Care and Outcomes in Mantle Cell Lymphoma in the Modern Immunochemotherapy Era. <i>Blood</i> , 2018 , 132, 4140-4140	2.2	
93	Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1603-1610	2.2	63

92	Low Plasma Omega-3 Fatty Acid Levels May Predict Inferior Prognosis in Untreated Diffuse Large B-Cell Lymphoma: A New Modifiable Dietary Biomarker?. <i>Nutrition and Cancer</i> , 2018 , 70, 1088-1090	2.8	3
91	Human Pegivirus infection and lymphoma risk and prognosis: a North American study. <i>British Journal of Haematology</i> , 2018 , 182, 644-653	4.5	15
90	CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies. <i>Blood Cancer Journal</i> , 2018 , 8, 63	7	9
89	Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma. <i>American Journal of Hematology</i> , 2017 , 92, 448-453	7.1	20
88	Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma. <i>British Journal of Haematology</i> , 2017 , 178, 427-433	4.5	10
87	Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. <i>JAMA Oncology</i> , 2017 , 3, 1257-1265	13.4	82
86	Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. <i>International Journal of Epidemiology</i> , 2017 , 46, 1753-1754	7.8	35
85	Frequency, risk factors, and outcomes of central nervous system relapse in lymphoma patients treated with dose-adjusted EPOCH plus rituximab. <i>American Journal of Hematology</i> , 2017 , 92, 1156-1162	7.1	6
84	Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy. <i>British Journal of Haematology</i> , 2017 , 179, 50-60	4.5	37
83	Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery. <i>Oncotarget</i> , 2017 , 8, 27145-27154	3.3	40
82	Retinoic acid receptor alpha drives cell cycle progression and is associated with increased sensitivity to retinoids in T-cell lymphoma. <i>Oncotarget</i> , 2017 , 8, 26245-26255	3.3	13
81	Vitamin D Insufficiency Is Associated with an Increased Risk of Early Clinical Failure in Follicular Lymphoma. <i>Blood</i> , 2016 , 128, 1104-1104	2.2	1
80	Treatment and Clinical Outcomes of High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements (Double Hit/Triple Hit Lymphomas). <i>Blood</i> , 2016 , 128, 155-155	2.2	1
79	An International Collaborative Study of Outcome and Prognostic Factors in Patients with Secondary CNS Involvement By Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016 , 128, 1874-1874	2.2	2
78	Lenalidomide Plus R-CHOP (R2CHOP) in Patients with DLBCL Is Associated with a Lower Risk of CNS Relapse: Combined Analysis from Two Phase 2 Studies. <i>Blood</i> , 2016 , 128, 3033-3033	2.2	2
77	Time from Diagnosis to Initiation of Treatment of DLBCL and Implication for Potential Selection Bias in Clinical Trials. <i>Blood</i> , 2016 , 128, 3034-3034	2.2	4
76	Lenalidomide Combined with R-CHOP (R2CHOP) Overcomes Negative Prognostic Impact of ABC Molecular Subtype in Newly Diagnosed Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016 , 128, 3035-3035	2.2	3
75	Outcomes of DLBCL Patients Entering Surveillance (without maintenance) after Immunochemotherapy in a Large Observational Study. <i>Blood</i> , 2016 , 128, 3036-3036	2.2	

74	Lenalidomide Plus R-CHOP (R2CHOP) in Patients with Follicular Lymphoma: Data from a Phase 1/2 Study. <i>Blood</i> , 2016 , 128, 5322-5322	2.2	
73	Whole-Exome Analysis Reveals Novel Somatic Genomic Alterations Associated with Cell of Origin in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016 , 128, 2935-2935	2.2	
72	Retinoic Acid Receptor Alpha Expression Drives Cell-Cycle Progression and Is Associated with Increased Sensitivity to Retinoids in Peripheral T-Cell Lymphoma. <i>Blood</i> , 2016 , 128, 1749-1749	2.2	
71	ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. <i>Future Oncology</i> , 2016 , 12, 1553-63	3.6	66
70	Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	44
69	Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. <i>American Journal of Hematology</i> , 2016 , 91, 1096-1101	7.1	137
68	Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2015 , 1853, 1658-71	4.9	103
67	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41). <i>Oncologist</i> , 2015 , 20, 1149-53 ⁵⁻⁷		37
66	Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. <i>Journal of Clinical Oncology</i> , 2015 , 33, 251-7	2.2	268
65	The efficacy of ibrutinib in the treatment of Richter syndrome. <i>Blood</i> , 2015 , 125, 1676-8	2.2	57
64	A roadmap for discovery and translation in lymphoma. <i>Blood</i> , 2015 , 125, 2175-7	2.2	16
63	Evolution: IMiDs to PPMs, revolution in DLBCL?. <i>Blood</i> , 2015 , 126, 698-700	2.2	4
62	ABC, GCB, and Double-Hit Diffuse Large B-Cell Lymphoma: Does Subtype Make a Difference in Therapy Selection?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015 , e449-57	7.1	68
61	The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. <i>Blood</i> , 2015 , 126, 328-35	2.2	73
60	Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 699-704	2	10
59	Treatment Patterns and Outcomes of DLBCL after Failure of Front-Line Immunochemotherapy. <i>Blood</i> , 2015 , 126, 2683-2683	2.2	4
58	Incidence and Outcomes of Treatment Refractory Diffuse Large B-Cell Lymphoma in the Immunochemotherapy Era. <i>Blood</i> , 2015 , 126, 3992-3992	2.2	1
57	Everolimus Plus RCHOP-21 Is Safe and Highly Effective for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of the Phase I Trial NCCTG1085 (Alliance). <i>Blood</i> , 2015 , 126, 813-813	2.2	1

56	Randomized, phase III trial of the efficacy and safety of lenalidomide plus R-CHOP vs R-CHOP in patients with untreated ABC-type diffuse large B-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS8600-TPS8600	2.2	1
55	Prognostic Correlates and Outcomes of Relapsed T-Cell Acute Lymphoblastic Leukemia/Lymphoma: An Analysis of 41 Consecutive Patients. <i>Blood</i> , 2015 , 126, 3730-3730	2.2	
54	Study of the Subclonal Mutations in Primary Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015 , 126, 131-131	2.2	
53	Lymphocyte-to-Monocyte Ratio at Diagnosis and Survival in De Novo Double/Triple Hit Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015 , 126, 3885-3885	2.2	
52	Survival Trends in Adult T-Acute Lymphoblastic Leukemia / Lymphoma (ALL), a Comparative Analysis of 92 Patients By Year of Diagnosis. <i>Blood</i> , 2015 , 126, 2490-2490	2.2	
51	The Adverse Impact of Age and Central Nervous System Involvement on Survival in Adult T-ALL, an Analysis of 92 Consecutive Patients. <i>Blood</i> , 2015 , 126, 4993-4993	2.2	
50	Natural History of Central Nervous System Relapse in Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era. <i>Blood</i> , 2015 , 126, 1456-1456	2.2	
49	Genome-wide association study identifies five susceptibility loci for follicular lymphoma outside the HLA region. <i>American Journal of Human Genetics</i> , 2014 , 95, 462-71	11	74
48	Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma. <i>Clinical Cancer Research</i> , 2014 , 20, 2862-72	12.9	68
47	Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3272-8	2.2	206
46	Peripheral Blood Absolute Lymphocyte/Monocyte Ratio Recovery During RCHOP Treatment Cycles Predicts Clinical Outcomes In Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2013 , 122, 4306-4306	2.2	
45	Combination of Lenalidomide with R-CHOP (R2CHOP) Is Well-Tolerated and Effective As Initial Therapy for Aggressive B-Cell Lymphomas - A Phase II Study. <i>Blood</i> , 2012 , 120, 689-689	2.2	8
44	Diffuse Large B-Cell Transformation in Nodular Lymphocyte Predominant Hodgkin Lymphoma: Incidence, Risk Factors and Outcomes After a Forty-Year Experience From a Single Institution. <i>Blood</i> , 2012 , 120, 1525-1525	2.2	
43	Peripheral Blood Absolute Lymphocyte/Monocyte Ratio At Diagnosis Is Independent of the Interim Positron-Emission Tomography in Predicting Progression-Free Survival and Time to Progression in Classical Hodgkin Lymphoma (HL). <i>Blood</i> , 2012 , 120, 1527-1527	2.2	
42	The Presence of Intratumoral CD14 Positive Cells Is Associated with Transformation of Follicular Lymphoma to Diffuse Large B Cell Lymphoma.. <i>Blood</i> , 2012 , 120, 2700-2700	2.2	2
41	Impact of Obesity and Genetic Variation in Energy Balance and Metabolism Genes On Prognosis in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). <i>Blood</i> , 2012 , 120, 684-684	2.2	
40	LR-CD: Efficacy of Combination Therapy with Lenalidomide for Untreated Indolent B-Cell NHL.. <i>Blood</i> , 2012 , 120, 2741-2741	2.2	
39	Germline Genetic Variation and Risk of Follicular Lymphoma Transformation in the Modern Treatment Era. <i>Blood</i> , 2012 , 120, 149-149	2.2	

38	Non-Follicular Low Grade B-Cell Lymphomas: Patterns of Presentation and Management with Comparative Prognostic Utility of IPI and FLIPI. <i>Blood</i> , 2012 , 120, 1563-1563	2.2	
37	Peripheral Blood Absolute Lymphocyte/Monocyte Ratio Recovery During ABVD Treatment Cycles Predicts Clinical Outcomes in Classical Hodgkin Lymphoma (HL).. <i>Blood</i> , 2012 , 120, 2634-2634	2.2	
36	Primary Parotid MALT Lymphoma: Clinical Characteristics and Treatment In Single Institution Experience. <i>Blood</i> , 2011 , 118, 1580-1580	2.2	1
35	Prior Rituximab Exposure Does Not Appear to Affect Time to Treatment Failure After Radioimmunotherapy. <i>Blood</i> , 2011 , 118, 1640-1640	2.2	1
34	Resistance to Complement Dependent Cytotoxicity in CLL Cells From Patients Treated with Ofatumumab. <i>Blood</i> , 2011 , 118, 2836-2836	2.2	1
33	Peripheral Blood Lymphocyte/Monocyte Ratio At Diagnosis Is Independent of the Cell of Origin in Predicting Survival in Diffuse Large B-Cell Lymphoma,. <i>Blood</i> , 2011 , 118, 3652-3652	2.2	
32	Utility of Stem Cell Collection in Anticipation of Future Need for Autologous Stem Cell Transplant in Follicular Lymphoma Patients. <i>Blood</i> , 2011 , 118, 1926-1926	2.2	
31	Risk of Transformation of Follicular Lymphoma to High Grade Lymphoma After Radioimmunotherapy: A Prospective Observational Single Institutional Experience. <i>Blood</i> , 2011 , 118, 1572-1572	2.2	
30	Peripheral Blood Lymphocyte/Monocyte Ratio At Diagnosis and Survival in Nodular Lymphocyte-Predominant Hodgkin Lymphoma,. <i>Blood</i> , 2011 , 118, 3642-3642	2.2	
29	The Absolute Monocyte Count Predicts Overall Survival In Patients Newly Diagnosed with Follicular Lymphoma. <i>Blood</i> , 2011 , 118, 85-85	2.2	
28	Phase I Trial of a Novel Combination of An HDAC Inhibitor (LBH589) and An mTOR Inhibitor (RAD001) in Lymphoid and Plasma Cell Malignancies. <i>Blood</i> , 2011 , 118, 2682-2682	2.2	
27	Potential Pathogenetic Role of Achromobacter (Alcaligenes) Xylosoxidans in Primary Extranodal Marginal Zone Lymphoma of the Lung (BALT-Lymphoma): Update of the Results of a Retrospective Analysis on Behalf of IELSG. <i>Blood</i> , 2011 , 118, 880-880	2.2	0
26	Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era. <i>Journal of Clinical Oncology</i> , 2010 , 28, 412-7	2.2	65
25	Phase 1 Trial of Sorafenib and Everolimus In Patients with Lymphoma or Multiple Myeloma.. <i>Blood</i> , 2010 , 116, 2802-2802	2.2	2
24	A Phase II Study of the Farnesyltransferase Inhibitor Tipifarnib Demonstrates Anti-Tumor Activity In Patients with Relapsed and Refractory Lymphomas. <i>Blood</i> , 2010 , 116, 287-287	2.2	0
23	Primary Pulmonary MALT Lymphoma: Clinical Characteristics and Treatment Outcomes In Single Institution Experience. <i>Blood</i> , 2010 , 116, 4168-4168	2.2	0
22	Genetic Polymorphisms In Genes Involved In R-CHOP Metabolism and Event-Free and Overall Survival In Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2010 , 116, 996-996	2.2	2
21	The Absolute Monocyte and Lymphocyte Counts at Diagnosis Predict Survival and Identify High-Risk Patients In Diffuse Large-B-Cell Lymphoma. <i>Blood</i> , 2010 , 116, 3088-3088	2.2	

20	Elevation of Serum Free Light Chains Are Common In Lymphoma and Associated with Poor Event Free and Overall Survival. <i>Blood</i> , 2010 , 116, 4136-4136	2.2	
19	Interactions with the Microenvironment Protect Lymphoma B-Cells From Rituximab Induced Apoptosis and Could Represent a Therapeutic Target. <i>Blood</i> , 2010 , 116, 3115-3115	2.2	
18	Phase II Clinical Trial of Denileukin Diftitox In Combination with Rituximab In Previously Untreated Follicular B-Cell Non-Hodgkin's Lymphoma. <i>Blood</i> , 2010 , 116, 2862-2862	2.2	
17	Reply to R.S. Go. <i>Journal of Clinical Oncology</i> , 2009 , 27, e45-e45	2.2	1
16	Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1844-9	2.2	56
15	Somatic Hyperrepair: A Novel Tumor Suppression Mechanism for Germinal Center B Cells.. <i>Blood</i> , 2009 , 114, 92-92	2.2	1
14	Cytogenetic Analysis of Normal Human B Cells Following CpG Stimulation: Implications for Interpretation of CpG Induced CLL Metaphase Analysis. <i>Blood</i> , 2008 , 112, 3124-3124	2.2	1
13	Using smudge cells on routine blood smears to predict clinical outcome in chronic lymphocytic leukemia: a universally available prognostic test. <i>Mayo Clinic Proceedings</i> , 2007 , 82, 449-53	6.4	47
12	Crosstalk between Chronic Lymphocytic Leukemia (CLL) B-Cells and Marrow Stromal Cells: Implication for CLL B-Cell Activation and Survival.. <i>Blood</i> , 2007 , 110, 337-337	2.2	
11	Increased Cytotoxic T-Cell Infiltrates in the Bone Marrow Is an Independent Adverse Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma.. <i>Blood</i> , 2007 , 110, 1492-1492	2.2	
10	A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 6087-93	12.9	105
9	Smudge Cells on Routine Blood Smear Predict Clinical Outcome in Chronic Lymphocytic Leukemia: A Universally Available Prognostic Test.. <i>Blood</i> , 2006 , 108, 2785-2785	2.2	1
8	Initial Presentation and Prognostic Factors in 286 Patients with T-Cell Large Granular Lymphocyte Leukemia.. <i>Blood</i> , 2006 , 108, 300-300	2.2	4
7	Neuropilin-1 Receptor (NRP-1) Occupancy Induces Cell Death in Primary Chronic Lymphocytic Leukemia (CLL) B Cells.. <i>Blood</i> , 2006 , 108, 586-586	2.2	
6	Human leucocyte antigen class I and killer immunoglobulin-like receptor expression patterns in T-cell large granular lymphocyte leukaemia. <i>British Journal of Haematology</i> , 2005 , 128, 490-2	4.5	18
5	Proteomic Analysis of Chronic Lymphocytic Leukemia Cells Identifies Vimentin as a Novel Prognostic Factor for Aggressive Disease.. <i>Blood</i> , 2005 , 106, 707-707	2.2	7
4	Prognostic Factors and Survival of Patients with Primary Mediastinal Large B-Cell Lymphoma.. <i>Blood</i> , 2005 , 106, 4698-4698	2.2	
3	Targeting V α -4 Reduces Cell Adhesion Mediated Drug Resistance in Chronic Lymphocytic Leukemia: Rationale for Anti V α -4 Therapy.. <i>Blood</i> , 2005 , 106, 1182-1182	2.2	

- | | | | |
|---|---|-----|---|
| 2 | Interphase Fluorescence In Situ Hybridization (FISH) with an IgH Probe Is Important in the Management of Patients with a Clinical Diagnosis of Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2004 , 104, 1919-1919 | 2.2 | 1 |
| 1 | Acquired Pure Red Cell Aplasia Associated with Clonal T-Cell Receptor (TCR) Gene Rearrangements with and without Pathologic Features of T-Cell Large Granular Lymphocytic Leukemia (T-LGLL).. <i>Blood</i> , 2004 , 104, 2819-2819 | 2.2 | |